• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B5 filed by Aditxt Inc.

    12/12/25 5:28:35 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADTX alert in real time by email
    424B5 1 ea0269074-424b5_aditxt.htm PROSPECTUS SUPPLEMENT

    Filed pursuant to Rule 424(b)(5)

    Registration No. 333-280757

    SUPPLEMENT NO. 2 TO

    PROSPECTUS SUPPLEMENT DATED OCTOBER 25, 2024

    (To Prospectus dated August 6, 2024)

     

     

     

    Up to $20,000,000

    Common Stock

     

    This prospectus supplement amends and supplements the prospectus dated August 6, 2024, filed as a part of our registration statement on Form S-3 (File No. 333-280757) as amended by our prospectus supplements dated October 25, 2024 and April 3, 2025 (the “Prior Prospectuses”). This prospectus supplement should be read in conjunction with the Prior Prospectuses, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectuses. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectuses, and any future amendments or supplements thereto.

     

    We filed the Prior Prospectuses to register the offer and sale of our common stock, par value $0.001 per share, from time to time pursuant to the terms of that certain At The Market Offering Agreement, or the sales agreement, between H.C. Wainwright & Co., LLC, or Wainwright, acting as the agent, and us (the “ATM Offering”).

     

    We are filing this prospectus supplement to amend the Prior Prospectuses to increase the maximum aggregate gross sales price of our common stock that may be offered, issued and sold under the sales agreement from and after the date hereof to $20,000,000 (the “ATM Offering Size Increase”), not including the shares of common stock previously sold. Under the prospectus supplement dated October 25, 2024, we initially registered up to $35,000,000 of our common stock for offer and sale pursuant to the sales agreement, which was reduced to $11,840,454 pursuant to the prospectus supplement dated April 3, 2025. As of the date of the filing of this prospectus supplement, we have sold 1,370,607 shares of our common stock that are covered by the Prior Prospectuses pursuant to the sales agreement for an aggregate gross sales proceeds of $17,771,951.

     

    The purpose of this prospectus supplement is to update the Prior Prospectuses to reflect the ATM Offering Size Increase. Except as modified by this prospectus supplement, the terms of the ATM Offering remain unchanged, and the sales agreement remains in full force and effect.

     

    Our prior prospectus supplement dated April 3, 2025 indicated that we were, at that time, subject to General Instruction I.B.6. of Form S-3, which limited the amount that we were able to sell under the registration statement of which the prospectus forms a part. We are currently no longer subject to the offering limits imposed by General Instruction I.B.6. of Form S-3. If we become subject to the offering limits in General Instruction I.B.6. of Form S-3 in the future, we will file another prospectus supplement.

     

    Our common stock is traded on The Nasdaq Capital Market under the symbol “ADTX.” On December 12, 2025, the last reported sale price of our common Stock as reported on the Nasdaq Capital Market was $2.24 per share.

     

    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

     

    H.C. Wainwright & Co.

     

    The date of this prospectus supplement is December 12, 2025.

     

     

     

     

    Get the next $ADTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ADTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

    Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most

    3/19/26 8:15:00 AM ET
    $ADTX
    $GMRE
    $XRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

    Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options. Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC ("Ignite"), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite's functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captured by standard genomic testing alone. Aditxt

    3/13/26 8:15:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

    Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-8 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on March 9, 2026, the Company's common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company's stockholders at the reconvened special meeting held on February 13, 2026, with the final ratio determined by the Company's board of directors. As a result of the reverse stock split, the CUSIP number for the Company's common stock will now be 007025877. As a r

    3/5/26 8:30:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    SEC Filings

    View All

    Aditxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Aditxt, Inc. (0001726711) (Filer)

    3/13/26 8:35:24 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aditxt Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Aditxt, Inc. (0001726711) (Filer)

    3/5/26 8:30:35 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aditxt Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Aditxt, Inc. (0001726711) (Filer)

    2/13/26 5:03:05 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $23,454 worth of Class A Shares (15,636 units at $1.50) and sold $29,875 worth of Class A Shares (25,534 units at $1.17), closing all direct ownership in the company (SEC Form 4)

    4 - Aditxt, Inc. (0001726711) (Issuer)

    10/17/24 1:58:54 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dawson James initiated coverage on ADiTx Therapeutics

    Dawson James initiated coverage of ADiTx Therapeutics with a rating of Buy

    2/4/21 8:32:09 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Brady Brian Michael sold $2 worth of shares (1 units at $1.75), decreasing direct ownership by 25% to 3 units (SEC Form 4)

    4 - Aditxt, Inc. (0001726711) (Issuer)

    12/19/25 5:00:02 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief M&A Officer Pankovcin Corinne sold $3 worth of shares (1 units at $3.20), closing all direct ownership in the company (SEC Form 4)

    4 - Aditxt, Inc. (0001726711) (Issuer)

    11/26/25 4:30:18 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Porcelli Christopher Jon claimed no ownership of stock in the company (SEC Form 3)

    3 - Aditxt, Inc. (0001726711) (Issuer)

    10/3/25 8:00:06 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    Financials

    Live finance-specific insights

    View All

    Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

    Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options. Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC ("Ignite"), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite's functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captured by standard genomic testing alone. Aditxt

    3/13/26 8:15:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

    -- Increased Net Sales and Improved Loss from Operations in Q2 2025 vs. Prior Year Quarter -- -- Evofem Advances Plans for Special Meeting of Stockholders to Approve the A&R Merger Agreement and Become a Wholly-owned Subsidiary of Aditxt --  SAN DIEGO, Aug. 14, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and six-month periods ended June 30, 2025 and provided a business update. Notable developments since April 1st include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Bioscienc

    8/14/25 8:46:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evofem Reports Fourth Consecutive Year of Net Sales Growth

    -- 2024 Net Sales Increased 6% to $19.4 Million -- -- Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense -- -- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch -- SAN DIEGO, March 24, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:E

    3/24/25 8:30:00 AM ET
    $ADTX
    $EVFM
    $WINT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ADTX
    Leadership Updates

    Live Leadership Updates

    View All

    Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

    Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most

    3/19/26 8:15:00 AM ET
    $ADTX
    $GMRE
    $XRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

    Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ("Evofem"), to Aditxt's Board of Directors. "We believe that Saundra's background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement our current Board well. We look forward to her contributions at this critical stage as we seek to execute our growth strategy for the overall business, transition Aditxt to a commercial stage company, and advance our plans to build a vertical focus on monitoring, prevention and treatment

    6/9/25 8:15:00 AM ET
    $ADTX
    $WINT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

    Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 2025, to discuss key findings from the newly announced preclinical study evaluating ADI-100™, the lead therapeutic candidate developed by its wholly owned subsidiary, Adimune™, Inc. ("Adimune"). Featured participants will include Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt, Inc., and Dr. Friedrich Kapp, Co-Chief Executive Offic

    4/17/25 8:15:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Aditxt Inc. (Amendment)

    SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

    2/14/24 2:14:47 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Aditxt Inc. (Amendment)

    SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

    2/6/24 10:06:47 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Aditxt Inc. (Amendment)

    SC 13G/A - Aditxt, Inc. (0001726711) (Subject)

    1/2/24 3:10:18 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care